The Assessment of SpondyloArthritis International Society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis.

Poddubnyy, Denis, Navarro-Compán, Victoria, Torgutalp, Murat, Arends, Suzanne, Aydin, Sibel Zehra, Battista, Simone, van den Bosch, Filip, Bundy, Christine ORCID: https://orcid.org/0000-0002-5981-3984, Cauli, Alberto, Davies, Jo, Dougados, Maxime, Duruöz, Tuncay, El-Zorkany, Bassel, Fong, Warren, van Gaalen, Floris, Garcia-Salinas, Rodrigo, Garrido Cumbrera, Marco, Géher, Pál, Gensler, Lianne, Grazio, Simeon, Huang, Feng, Kishimoto, Mitsumasa, Landewé, Robert, Leung, Ying Ying, Machado, Pedro M, Marzo-Ortega, Helena, Meghnathi, Bhowmik, Molto, Anna, Nikiphorou, Elena, Ramiro, Sofia, Rudwaleit, Martin, Saad, Carla G S, Sepriano, Alexandre, Wei, James, Baraliakos, Xenofon, van der Heijde, Désirée and ASAS 2025. The Assessment of SpondyloArthritis International Society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis. Annals of the Rheumatic Diseases 10.1016/j.ard.2025.01.035

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB)

Abstract

To develop a consensus-based expert definition of difficult-to-manage (D2M) axial spondyloarthritis (axSpA), incorporating treatment-refractory (TR) disease. A literature review was conducted in 2022 to identify potential definitions for D2M/TR axSpA from prior studies, followed by a 2-round Delphi consensus process conducted in 2022 and 2023 to identify components of D2M axSpA. Based on the results of the Delphi process, a draft of the D2M axSpA definition was developed and presented to the expert task force, including patient representation, and, subsequently, to the Assessment of SpondyloArthritis International Society (ASAS) membership for endorsement in January 2024. Consensus was reached on a D2M definition encapsulating treatment failure (treatment according to the ASAS-European Alliance of Associations for Rheumatology recommendations and failure of ≥2 biological or targeted synthetic disease-modifying antirheumatic drugs with different mechanisms of action unless contraindicated), suboptimal disease control, and physician or patient acknowledgement of problematic signs/symptoms in patients diagnosed with axSpA by the rheumatologist. This definition represents a broad concept that includes various reasons that lead to an unsatisfactory treatment outcome. TR axSpA is covered by the D2M definition but requires a history of treatment failure, the presence of objective signs of inflammatory activity, and the exclusion of noninflammatory reasons for nonresponse. The proposed D2M definition incorporating TR disease was endorsed by ASAS at the annual meeting in January 2024, with 89% votes (109/123) in favour of it. The ASAS D2M axSpA definition, including TR disease, allows for identifying patients with unmet needs, paving the way for further research in this condition and its clinical care improvement. [Abstract copyright: Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.]

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Schools > Healthcare Sciences
Publisher:	BMJ Publishing Group
ISSN:	0003-4967
Date of First Compliant Deposit:	5 March 2025
Date of Acceptance:	16 January 2025
Last Modified:	05 Mar 2025 11:00
URI:	https://orca.cardiff.ac.uk/id/eprint/176625

Actions (repository staff only)

Edit Item